Tags

Type your tag names separated by a space and hit enter

Clinical and economic characteristics of patients with fibromyalgia syndrome.
Clin J Pain. 2010 May; 26(4):284-90.CJ

Abstract

OBJECTIVES

Fibromyalgia syndrome (FMS) is a chronic disorder defined by widespread muscle pain and multiple tender points. The objectives of this study were to estimate prevalence of comorbidities, healthcare resources utilization, and costs associated with FMS.

METHODS

A retrospective cohort study was conducted using data from the Quebec provincial health plans (RAMQ) for a random sample of patients with diagnoses of FMS and a control cohort of patients without FMS, matched for age and gender. Prevalence of comorbidities was estimated. Healthcare resources consumed by FMS and non-FMS patients were identified in terms of visits to physicians, physician's interventions, pain-related medications, nonpain-related medications, and hospitalizations.

RESULTS

A total of 16,010 patients with 2 diagnoses of FMS were identified, and control patients were randomly selected with a ratio of 1:1. Incidence of most comorbidities was significantly higher in the FMS group and the chronic disease score (3.8 vs. 2.8; ANOVA P <0.001). The proportion of patients with at least 1 comorbidity was 87.4% in the FMS group and 60.1% in the control group (chiP<0.001). The annual number of visits to physician and physician's interventions was 25.1 for FMS and 14.8 for non-FMS patients. The amount paid by the RAMQ was significantly higher for patients with FMS ($4065) compared with patients without FMS ($2766) (ANOVA P<0.001).

DISCUSSION

Results of this analysis of the RAMQ database illustrate the high prevalence of comorbidities among patients with a diagnosis of FMS and strongly indicate that the economic burden of FMS is substantial.

Authors+Show Affiliations

Faculty of Pharmacy, University of Montreal, Montreal, Canada. jean.Lachaine@umontreal.caNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20393262

Citation

Lachaine, Jean, et al. "Clinical and Economic Characteristics of Patients With Fibromyalgia Syndrome." The Clinical Journal of Pain, vol. 26, no. 4, 2010, pp. 284-90.
Lachaine J, Beauchemin C, Landry PA. Clinical and economic characteristics of patients with fibromyalgia syndrome. Clin J Pain. 2010;26(4):284-90.
Lachaine, J., Beauchemin, C., & Landry, P. A. (2010). Clinical and economic characteristics of patients with fibromyalgia syndrome. The Clinical Journal of Pain, 26(4), 284-90. https://doi.org/10.1097/AJP.0b013e3181cf599f
Lachaine J, Beauchemin C, Landry PA. Clinical and Economic Characteristics of Patients With Fibromyalgia Syndrome. Clin J Pain. 2010;26(4):284-90. PubMed PMID: 20393262.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical and economic characteristics of patients with fibromyalgia syndrome. AU - Lachaine,Jean, AU - Beauchemin,Catherine, AU - Landry,Pierre-Alexandre, PY - 2010/4/16/entrez PY - 2010/4/16/pubmed PY - 2010/7/9/medline SP - 284 EP - 90 JF - The Clinical journal of pain JO - Clin J Pain VL - 26 IS - 4 N2 - OBJECTIVES: Fibromyalgia syndrome (FMS) is a chronic disorder defined by widespread muscle pain and multiple tender points. The objectives of this study were to estimate prevalence of comorbidities, healthcare resources utilization, and costs associated with FMS. METHODS: A retrospective cohort study was conducted using data from the Quebec provincial health plans (RAMQ) for a random sample of patients with diagnoses of FMS and a control cohort of patients without FMS, matched for age and gender. Prevalence of comorbidities was estimated. Healthcare resources consumed by FMS and non-FMS patients were identified in terms of visits to physicians, physician's interventions, pain-related medications, nonpain-related medications, and hospitalizations. RESULTS: A total of 16,010 patients with 2 diagnoses of FMS were identified, and control patients were randomly selected with a ratio of 1:1. Incidence of most comorbidities was significantly higher in the FMS group and the chronic disease score (3.8 vs. 2.8; ANOVA P <0.001). The proportion of patients with at least 1 comorbidity was 87.4% in the FMS group and 60.1% in the control group (chiP<0.001). The annual number of visits to physician and physician's interventions was 25.1 for FMS and 14.8 for non-FMS patients. The amount paid by the RAMQ was significantly higher for patients with FMS ($4065) compared with patients without FMS ($2766) (ANOVA P<0.001). DISCUSSION: Results of this analysis of the RAMQ database illustrate the high prevalence of comorbidities among patients with a diagnosis of FMS and strongly indicate that the economic burden of FMS is substantial. SN - 1536-5409 UR - https://www.unboundmedicine.com/medline/citation/20393262/Clinical_and_economic_characteristics_of_patients_with_fibromyalgia_syndrome_ L2 - https://doi.org/10.1097/AJP.0b013e3181cf599f DB - PRIME DP - Unbound Medicine ER -